The national cohort CKD-REIN (Chronic Kidney Disease - Network Epidemiology and Information in Nephrology) is supported by the program "Investment for the future" funded by the ANR for 10 years. 3000 French patients with chronic renal diseases of all types have been included and will be followed over 5 years. Blood and urine samples will be taken at three times (inclusion, follow-up at two and five years). The size of this cohort generates data that will meet the many objectives: to slow the progression of the disease, prevent associated damage, delay the use of dialysis or prevent it from being started too late, improve medical practices and ensure a better quality of life for patients.
For more information see the site CKD REIN .
The Dlay MS project is a national PHRC obtained in 2012 by Professor Eric THOUVENOT (University Hospital of Nîmes). This is a multicentre, randomized, double-blind placebo-controlled study evaluating the efficacy of Cholecalciferol (Vitamin D) treatment in delaying the diagnosis of multiple sclerosis (MS) after a clinically isolated syndrome (CIS).
Many epidemiological arguments have demonstrated an association between vitamin D deficiency, the risk of multiple sclerosis, the activity of the disease and the degree of disability of patients.
The objective of this project is to determine if supplementation to achieve a physiological level of vitamin D brings a benefit to delay conversion after a CIS. Demonstration of the clinical and / or radiological efficacy of vitamin D supplementation would add safe and low-cost treatment to the therapeutic arsenal of MS.
A plasmathèque is associated with this study to evaluate the treatment during the disease by analyzing the different biological parameters.
The details of the project are available on the site clinicaltrials.gov (NCT01817166).
This study by Institut de Cancérologie de l’Ouest is a prospective, multicentre, uncontrolled, dose-escalation study followed by an extension cohort at the recommended dose. It consists of the oral administration of folic acid (at pharmacological doses) associated with temozolomide according to the scheme defined by Stupp in patients with operated grade IV astrocytoma (OMS), associated with an DNA gene status MGMT.
In order to evaluate this treatment, tumor and blood samples are taken before and after treatment to analyze the correlation between overall methylation status and MGMT with the combination of folinic acid and temozolomide.
The national Memento cohort (deterMinants and Evolution of Alzheimer's disEase aND relaTed disOrders) was set up by the Brodeaux University Hospital as part of the 2008-2012 Alzheimer Plan with the aim of describing and better understanding the clinical evolution of patients. with early signs that may suggest the onset of Alzheimer's disease or a related disease.
One of the major challenges of Memento is to measure, repeatedly in patients with these potential early signs, a series of biomarkers (magnetic resonance imaging or molecular PET imaging, genetic analyzes, biological measurements via blood or cerebrospinal fluid). spinal cord), risk factors (lifestyle, drug treatments, quality of life) and to monitor the evolution of their neurocognitive performance.
All these observations should make it possible to understand which parameters explain that some people become sick and others do not. In the longer term, the knowledge accumulated through the Memento study could help diagnose patients at an earlier stage and offer them treatments that will stop or slow the progression of the disease.
For more information visit the site MEMENTO.
Winner of the Horizon 2020 program of the 2014 European Research and the 2014 Hospital-Based Clinical Research Program, the MIROCALS project aims to study low-dose interleukin-2 as a new therapeutic approach to lateral sclerosis amyotrophic (ALS).
The primary objective of this phase 2, randomized, double-blind, placebo-controlled trial is to evaluate the safety and clinical efficacy of this treatment.
The secondary objective of this study is to evaluate in patients receiving treatment the biological markers of the response to low doses of IL-2 in relation to the clinical response.
The blood and cerebrospinal fluid samples taken during the study will be used to study the markers of neurodegeneration and immuno-inflammation, including regulatory T cells that are biological targets for treatment. Exploratory studies will identify new biomolecular targets through genomics.
For more information consult the MIROCALS website.
The OFSEP is a collaborative project funded by the National Agency for Research (ANR) and bringing together French neurologists and neuroradiologists specialists in this disease. The objective of this cohort is to collect, at the national level, clinical, biological and imaging information from all patients with Multiple Sclerosis MS and related diseases. Standard biological samples of blood, cerebrospinal fluid, urine and stool are made for the following pathologies:
• Radiologically isolated syndrome (RIS)
• Clinically isolated syndrome (CIS)
• Early progressive multiple sclerosis (PP MS)
• Acute neuro-optico-myelitis of Devic and related neurological syndromes (NOMADMUS)
• Acute disseminated encephalomyelitis (ADEM)
• Leuco progressive multifocal encephalopathy (PML)
Samples (serum, plasma, DNA, PBMC, CSF, urine, stool) are available after submission of a research project to OFSEP.
For more information visit the OFSEP website.
The Resting State Coma Study (RSC) is a prospective, case-based, multicenter study of stimulation of the vegetative function of unconscious patients, in collaboration with the Institute of Cognitive Sciences of Lyon (Pr Angela SIRIGU).
This research project aims to identify the mechanisms of action of vagus nerve stimulation on the waking system and the vegetative system, and to improve the cognitive state of patients upon waking.
The project focuses on the study of EEG patients in coma and the analysis of blood samples to discover potential biomarkers of brain activity in this pathology. The objective is therefore to correlate the measurements made (recorded brain activities and peripheral concentrations of neurotransmitters) with changes in the clinical state of the patients.